Catalog No.
RHC41801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Alpaca
Isotype
VHH-8His-Cys-tag
Clonality
Monoclonal
Target
GP40, CD7, T-cell surface antigen Leu-9, T-cell leukemia antigen, TP41, T-cell antigen CD7
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P09564
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1260
CD7-Targeted Cytotoxic Potency of Diphtheria Toxin- and Ricin-Based Immunotoxins in Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia., PMID:40317108
Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia., PMID:39561281
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma., PMID:35435984
Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma., PMID:35130959
Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies., PMID:34873460
A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia., PMID:30755812
Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential., PMID:28331319
Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells., PMID:27083001
For research use only. Not for human or drug use.
